JPMorgan Chase & Co. Reaffirms Overweight Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “overweight” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, Marketbeat reports.

Separately, Berenberg Bank upped their target price on shares of Hikma Pharmaceuticals from GBX 2,400 ($31.01) to GBX 2,560 ($33.08) and gave the stock a “buy” rating in a research report on Wednesday, January 29th.

Hikma Pharmaceuticals Price Performance

Shares of LON:HIK opened at GBX 2,123.65 ($27.44) on Friday. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,750 ($22.61) and a fifty-two week high of GBX 2,360 ($30.49). The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The company has a market cap of £5.89 billion, a PE ratio of 20.84, a P/E/G ratio of 2.38 and a beta of 0.41. The firm has a 50-day simple moving average of GBX 2,170.52 and a 200 day simple moving average of GBX 2,012.90.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.